Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025CancersOpen Access

Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions

View Full Paper
Ask AI
Bookmark
Share

Authors

SKSaid KhelwattySPSoozana PuvanenthiranASAlan M. Seddon

Discussion

Loading...

Member takes

Overview

This review explores targeted therapies, such as HER inhibitors, for colorectal cancer, highlighting challenges and novel biomarkers.

Key Points

  • Targeted therapies have transformed colorectal cancer treatment, yet challenges like resistance mechanisms remain.
  • Research shows that antibodies like cetuximab and panitumumab improve outcomes for CRC patients with wild-type KRAS.
  • Efforts include developing new therapies such as dual TKIs, antibody/drug conjugates, and CAR-T cells to combat CRC.
  • The diverse nature of colorectal cancer underscores the need for reliable biomarkers for better patient treatment selection.

Cite This Study

Khelwatty et al. (2025) studied this question.

synapsesocial.com/papers/68c23887b210217d64778701https://doi.org/10.3390/cancers17172810
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immunotherapy for Colorectal Cancer: Recent Advancements2025 · 7 citations
  2. 2Advances and challenges in drug repurposing in precision therapeutics of colorectal cancer2025
  3. 3New progress and challenges of targeted therapies for breast cancer2025 · 10 citations
  4. 4Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival2025 · 4 citations
  5. 5Molecular Basis, Diagnostic Approaches, and Therapeutic Strategies in Colorectal Cancer—Comprehensive Review2025